Clinical Trials for Rilotumumab
1 Open Trial
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCGI1269 01/28/2013 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
